Fig. 2From: A possible association of baseline serum IL-17A concentrations with progression-free survival of metastatic colorectal cancer patients treated with a bevacizumab-based regimenKaplan–Meier plots. Progression-free survival according to the score calculated by baseline concentrations of plasma VEGF and serum IL-17A and bevacizumab Ctrough. P = 0.0006 by log-rank testBack to article page